#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Altered functional connectivity of the nucleus accumbens subdivisions in amphetamine-type stimulant abusers: a resting-state fMRI study Background The growing abuse of amphetamine-type stimulants leads to new challenges to human health.
1-1	0-7	Altered	_
1-2	8-18	functional	_
1-3	19-31	connectivity	_
1-4	32-34	of	_
1-5	35-38	the	_
1-6	39-46	nucleus	_
1-7	47-56	accumbens	_
1-8	57-69	subdivisions	_
1-9	70-72	in	_
1-10	73-89	amphetamine-type	_
1-11	90-99	stimulant	_
1-12	100-107	abusers	_
1-13	108-109	:	_
1-14	110-111	a	_
1-15	112-125	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-16	126-130	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-17	131-136	study	_
1-18	137-147	Background	_
1-19	148-151	The	_
1-20	152-159	growing	_
1-21	160-165	abuse	_
1-22	166-168	of	_
1-23	169-185	amphetamine-type	_
1-24	186-196	stimulants	_
1-25	197-202	leads	_
1-26	203-205	to	_
1-27	206-209	new	_
1-28	210-220	challenges	_
1-29	221-223	to	_
1-30	224-229	human	_
1-31	230-236	health	_
1-32	237-238	.	_

Text=A possible addiction mechanism has been proposed by altered functional architecture of the nucleus accumbens (NAc) during resting state.
2-1	239-240	A	_
2-2	241-249	possible	_
2-3	250-259	addiction	_
2-4	260-269	mechanism	_
2-5	270-273	has	_
2-6	274-278	been	_
2-7	279-287	proposed	_
2-8	288-290	by	_
2-9	291-298	altered	_
2-10	299-309	functional	_
2-11	310-322	architecture	_
2-12	323-325	of	_
2-13	326-329	the	_
2-14	330-337	nucleus	_
2-15	338-347	accumbens	_
2-16	348-349	(	_
2-17	350-353	NAc	_
2-18	354-355	)	_
2-19	356-362	during	_
2-20	363-370	resting	_
2-21	371-376	state	_
2-22	377-378	.	_

Text=NAc contains different subdivisions and they may play different roles in addiction.
3-1	379-382	NAc	_
3-2	383-391	contains	_
3-3	392-401	different	_
3-4	402-414	subdivisions	_
3-5	415-418	and	_
3-6	419-423	they	_
3-7	424-427	may	_
3-8	428-432	play	_
3-9	433-442	different	_
3-10	443-448	roles	_
3-11	449-451	in	_
3-12	452-461	addiction	_
3-13	462-463	.	_

Text=The aim of the present study was to examine whether there are common or distinct patterns of functional connectivity of the NAc subdivisions in amphetamine-type stimulant abusers (ATSAs).
4-1	464-467	The	_
4-2	468-471	aim	_
4-3	472-474	of	_
4-4	475-478	the	_
4-5	479-486	present	_
4-6	487-492	study	_
4-7	493-496	was	_
4-8	497-499	to	_
4-9	500-507	examine	_
4-10	508-515	whether	_
4-11	516-521	there	_
4-12	522-525	are	_
4-13	526-532	common	_
4-14	533-535	or	_
4-15	536-544	distinct	_
4-16	545-553	patterns	_
4-17	554-556	of	_
4-18	557-567	functional	_
4-19	568-580	connectivity	_
4-20	581-583	of	_
4-21	584-587	the	_
4-22	588-591	NAc	_
4-23	592-604	subdivisions	_
4-24	605-607	in	_
4-25	608-624	amphetamine-type	_
4-26	625-634	stimulant	_
4-27	635-642	abusers	_
4-28	643-644	(	_
4-29	645-650	ATSAs	_
4-30	651-652	)	_
4-31	653-654	.	_

Text=Methods The present study recruited 17 male ATSAs and 22 healthy male controls.
5-1	655-662	Methods	_
5-2	663-666	The	_
5-3	667-674	present	_
5-4	675-680	study	_
5-5	681-690	recruited	_
5-6	691-693	17	_
5-7	694-698	male	_
5-8	699-704	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
5-9	705-708	and	_
5-10	709-711	22	_
5-11	712-719	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-12	720-724	male	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-13	725-733	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-14	734-735	.	_

Text=All the subjects underwent resting-state functional magnetic resonance imaging (fMRI) with their eyes closed.
6-1	736-739	All	_
6-2	740-743	the	_
6-3	744-752	subjects	_
6-4	753-762	underwent	_
6-5	763-776	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-6	777-787	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-7	788-796	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-8	797-806	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-9	807-814	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-10	815-816	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-11	817-821	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-12	822-823	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-13	824-828	with	_
6-14	829-834	their	_
6-15	835-839	eyes	_
6-16	840-846	closed	_
6-17	847-848	.	_

Text=The NAc was divided into core-like and shell-like subdivisions.
7-1	849-852	The	_
7-2	853-856	NAc	_
7-3	857-860	was	_
7-4	861-868	divided	_
7-5	869-873	into	_
7-6	874-883	core-like	_
7-7	884-887	and	_
7-8	888-898	shell-like	_
7-9	899-911	subdivisions	_
7-10	912-913	.	_

Text=We used seed-based resting-state functional connectivity (RSFC) analyses to identify differences in brain functional architecture between ATSAs and healthy controls (HCs).
8-1	914-916	We	_
8-2	917-921	used	_
8-3	922-932	seed-based	_
8-4	933-946	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
8-5	947-957	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
8-6	958-970	connectivity	_
8-7	971-972	(	_
8-8	973-977	RSFC	_
8-9	978-979	)	_
8-10	980-988	analyses	_
8-11	989-991	to	_
8-12	992-1000	identify	_
8-13	1001-1012	differences	_
8-14	1013-1015	in	_
8-15	1016-1021	brain	_
8-16	1022-1032	functional	_
8-17	1033-1045	architecture	_
8-18	1046-1053	between	_
8-19	1054-1059	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
8-20	1060-1063	and	_
8-21	1064-1071	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-22	1072-1080	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-23	1081-1082	(	_
8-24	1083-1086	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-25	1087-1088	)	_
8-26	1089-1090	.	_

Text=Results ATSAs had lower positive RSFCs with all of the NAc subdivisions over the left orbital part of superior frontal gyrus and higher positive RSFCs with the NAc subdivisions over the left opercular part of inferior frontal gyrus than HCs, which indicates common abnormalities across the NAc subdivisions in ATSAs.
9-1	1091-1098	Results	_
9-2	1099-1104	ATSAs	_
9-3	1105-1108	had	_
9-4	1109-1114	lower	_
9-5	1115-1123	positive	_
9-6	1124-1129	RSFCs	_
9-7	1130-1134	with	_
9-8	1135-1138	all	_
9-9	1139-1141	of	_
9-10	1142-1145	the	_
9-11	1146-1149	NAc	_
9-12	1150-1162	subdivisions	_
9-13	1163-1167	over	_
9-14	1168-1171	the	_
9-15	1172-1176	left	_
9-16	1177-1184	orbital	_
9-17	1185-1189	part	_
9-18	1190-1192	of	_
9-19	1193-1201	superior	_
9-20	1202-1209	frontal	_
9-21	1210-1215	gyrus	_
9-22	1216-1219	and	_
9-23	1220-1226	higher	_
9-24	1227-1235	positive	_
9-25	1236-1241	RSFCs	_
9-26	1242-1246	with	_
9-27	1247-1250	the	_
9-28	1251-1254	NAc	_
9-29	1255-1267	subdivisions	_
9-30	1268-1272	over	_
9-31	1273-1276	the	_
9-32	1277-1281	left	_
9-33	1282-1291	opercular	_
9-34	1292-1296	part	_
9-35	1297-1299	of	_
9-36	1300-1308	inferior	_
9-37	1309-1316	frontal	_
9-38	1317-1322	gyrus	_
9-39	1323-1327	than	_
9-40	1328-1331	HCs	_
9-41	1332-1333	,	_
9-42	1334-1339	which	_
9-43	1340-1349	indicates	_
9-44	1350-1356	common	_
9-45	1357-1370	abnormalities	_
9-46	1371-1377	across	_
9-47	1378-1381	the	_
9-48	1382-1385	NAc	_
9-49	1386-1398	subdivisions	_
9-50	1399-1401	in	_
9-51	1402-1407	ATSAs	_
9-52	1408-1409	.	_

Text=In addition, the RSFCs between the NAc subdivisions and the left orbital part of superior frontal gyrus were negatively correlated with the addiction severity in ATSAs.
10-1	1410-1412	In	_
10-2	1413-1421	addition	_
10-3	1422-1423	,	_
10-4	1424-1427	the	_
10-5	1428-1433	RSFCs	_
10-6	1434-1441	between	_
10-7	1442-1445	the	_
10-8	1446-1449	NAc	_
10-9	1450-1462	subdivisions	_
10-10	1463-1466	and	_
10-11	1467-1470	the	_
10-12	1471-1475	left	_
10-13	1476-1483	orbital	_
10-14	1484-1488	part	_
10-15	1489-1491	of	_
10-16	1492-1500	superior	_
10-17	1501-1508	frontal	_
10-18	1509-1514	gyrus	_
10-19	1515-1519	were	_
10-20	1520-1530	negatively	_
10-21	1531-1541	correlated	_
10-22	1542-1546	with	_
10-23	1547-1550	the	_
10-24	1551-1560	addiction	_
10-25	1561-1569	severity	_
10-26	1570-1572	in	_
10-27	1573-1578	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
10-28	1579-1580	.	_

Text=Conclusion These results provide evidence that there are common RSFC patterns of the NAc subdivisions in ATSAs.
11-1	1581-1591	Conclusion	_
11-2	1592-1597	These	_
11-3	1598-1605	results	_
11-4	1606-1613	provide	_
11-5	1614-1622	evidence	_
11-6	1623-1627	that	_
11-7	1628-1633	there	_
11-8	1634-1637	are	_
11-9	1638-1644	common	_
11-10	1645-1649	RSFC	_
11-11	1650-1658	patterns	_
11-12	1659-1661	of	_
11-13	1662-1665	the	_
11-14	1666-1669	NAc	_
11-15	1670-1682	subdivisions	_
11-16	1683-1685	in	_
11-17	1686-1691	ATSAs	_
11-18	1692-1693	.	_

Text=The abnormality indicated by disrupted functional connectivity between the NAc subdivisions and prefrontal cortex suggests abnormal interaction between the rewarding process and cognitive control in ATSAs.
12-1	1694-1697	The	_
12-2	1698-1709	abnormality	_
12-3	1710-1719	indicated	_
12-4	1720-1722	by	_
12-5	1723-1732	disrupted	_
12-6	1733-1743	functional	_
12-7	1744-1756	connectivity	_
12-8	1757-1764	between	_
12-9	1765-1768	the	_
12-10	1769-1772	NAc	_
12-11	1773-1785	subdivisions	_
12-12	1786-1789	and	_
12-13	1790-1800	prefrontal	_
12-14	1801-1807	cortex	_
12-15	1808-1816	suggests	_
12-16	1817-1825	abnormal	_
12-17	1826-1837	interaction	_
12-18	1838-1845	between	_
12-19	1846-1849	the	_
12-20	1850-1859	rewarding	_
12-21	1860-1867	process	_
12-22	1868-1871	and	_
12-23	1872-1881	cognitive	_
12-24	1882-1889	control	_
12-25	1890-1892	in	_
12-26	1893-1898	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
12-27	1899-1900	.	_

Text=Our results shed insight on the neurobiological mechanisms of ATSA and suggest potential novel therapeutic targets for treatment and intervention of ATSAs.
13-1	1901-1904	Our	_
13-2	1905-1912	results	_
13-3	1913-1917	shed	_
13-4	1918-1925	insight	_
13-5	1926-1928	on	_
13-6	1929-1932	the	_
13-7	1933-1948	neurobiological	_
13-8	1949-1959	mechanisms	_
13-9	1960-1962	of	_
13-10	1963-1967	ATSA	http://maven.renci.org/NeuroBridge/neurobridge#Thing
13-11	1968-1971	and	_
13-12	1972-1979	suggest	_
13-13	1980-1989	potential	_
13-14	1990-1995	novel	_
13-15	1996-2007	therapeutic	_
13-16	2008-2015	targets	_
13-17	2016-2019	for	_
13-18	2020-2029	treatment	_
13-19	2030-2033	and	_
13-20	2034-2046	intervention	_
13-21	2047-2049	of	_
13-22	2050-2055	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
13-23	2056-2057	.	_

Text=Materials and methods Subjects Male ATSAs (n = 17) were recruited from the Wuhan Mental Health Centre affiliated with the Huazhong University of Science and Technology during the period from October 2012 to December 2012.
14-1	2058-2067	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-2	2068-2071	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-3	2072-2079	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-4	2080-2088	Subjects	_
14-5	2089-2093	Male	_
14-6	2094-2099	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
14-7	2100-2101	(	_
14-8	2102-2103	n	_
14-9	2104-2105	=	_
14-10	2106-2108	17	_
14-11	2109-2110	)	_
14-12	2111-2115	were	_
14-13	2116-2125	recruited	_
14-14	2126-2130	from	_
14-15	2131-2134	the	_
14-16	2135-2140	Wuhan	_
14-17	2141-2147	Mental	_
14-18	2148-2154	Health	_
14-19	2155-2161	Centre	_
14-20	2162-2172	affiliated	_
14-21	2173-2177	with	_
14-22	2178-2181	the	_
14-23	2182-2190	Huazhong	_
14-24	2191-2201	University	_
14-25	2202-2204	of	_
14-26	2205-2212	Science	_
14-27	2213-2216	and	_
14-28	2217-2227	Technology	_
14-29	2228-2234	during	_
14-30	2235-2238	the	_
14-31	2239-2245	period	_
14-32	2246-2250	from	_
14-33	2251-2258	October	_
14-34	2259-2263	2012	_
14-35	2264-2266	to	_
14-36	2267-2275	December	_
14-37	2276-2280	2012	_
14-38	2281-2282	.	_

Text=Healthy male controls (n = 22) were recruited from the local community and Huazhong University of Science and Technology by advertisements.
15-1	2283-2290	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-2	2291-2295	male	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-3	2296-2304	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-4	2305-2306	(	_
15-5	2307-2308	n	_
15-6	2309-2310	=	_
15-7	2311-2313	22	_
15-8	2314-2315	)	_
15-9	2316-2320	were	_
15-10	2321-2330	recruited	_
15-11	2331-2335	from	_
15-12	2336-2339	the	_
15-13	2340-2345	local	_
15-14	2346-2355	community	_
15-15	2356-2359	and	_
15-16	2360-2368	Huazhong	_
15-17	2369-2379	University	_
15-18	2380-2382	of	_
15-19	2383-2390	Science	_
15-20	2391-2394	and	_
15-21	2395-2405	Technology	_
15-22	2406-2408	by	_
15-23	2409-2423	advertisements	_
15-24	2424-2425	.	_

Text=The inclusion criteria for both groups were as follows: 18–40 years of age, male, at least 9 years of education, normal or corrected-to-normal hearing and vision, and no reported history of neurological problems, ophthalmic diseases, or severe head injuries.
16-1	2426-2429	The	_
16-2	2430-2439	inclusion	_
16-3	2440-2448	criteria	_
16-4	2449-2452	for	_
16-5	2453-2457	both	_
16-6	2458-2464	groups	_
16-7	2465-2469	were	_
16-8	2470-2472	as	_
16-9	2473-2480	follows	_
16-10	2481-2482	:	_
16-11	2483-2488	18–40	_
16-12	2489-2494	years	_
16-13	2495-2497	of	_
16-14	2498-2501	age	_
16-15	2502-2503	,	_
16-16	2504-2508	male	_
16-17	2509-2510	,	_
16-18	2511-2513	at	_
16-19	2514-2519	least	_
16-20	2520-2521	9	_
16-21	2522-2527	years	_
16-22	2528-2530	of	_
16-23	2531-2540	education	_
16-24	2541-2542	,	_
16-25	2543-2549	normal	_
16-26	2550-2552	or	_
16-27	2553-2572	corrected-to-normal	_
16-28	2573-2580	hearing	_
16-29	2581-2584	and	_
16-30	2585-2591	vision	_
16-31	2592-2593	,	_
16-32	2594-2597	and	_
16-33	2598-2600	no	_
16-34	2601-2609	reported	_
16-35	2610-2617	history	_
16-36	2618-2620	of	_
16-37	2621-2633	neurological	_
16-38	2634-2642	problems	_
16-39	2643-2644	,	_
16-40	2645-2655	ophthalmic	_
16-41	2656-2664	diseases	_
16-42	2665-2666	,	_
16-43	2667-2669	or	_
16-44	2670-2676	severe	_
16-45	2677-2681	head	_
16-46	2682-2690	injuries	_
16-47	2691-2692	.	_

Text=All enrolled ATSAs met the Diagnostic and Statistical Manual for Mental Disorders, 4th Edition (DSM-IV) criteria for drug dependence and were assessed using the Chinese version of the Addiction Severity Index (ASI-C).
17-1	2693-2696	All	_
17-2	2697-2705	enrolled	_
17-3	2706-2711	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
17-4	2712-2715	met	_
17-5	2716-2719	the	_
17-6	2720-2730	Diagnostic	_
17-7	2731-2734	and	_
17-8	2735-2746	Statistical	_
17-9	2747-2753	Manual	_
17-10	2754-2757	for	_
17-11	2758-2764	Mental	_
17-12	2765-2774	Disorders	_
17-13	2775-2776	,	_
17-14	2777-2780	4th	_
17-15	2781-2788	Edition	_
17-16	2789-2790	(	_
17-17	2791-2797	DSM-IV	_
17-18	2798-2799	)	_
17-19	2800-2808	criteria	_
17-20	2809-2812	for	_
17-21	2813-2817	drug	_
17-22	2818-2828	dependence	_
17-23	2829-2832	and	_
17-24	2833-2837	were	_
17-25	2838-2846	assessed	_
17-26	2847-2852	using	_
17-27	2853-2856	the	_
17-28	2857-2864	Chinese	_
17-29	2865-2872	version	_
17-30	2873-2875	of	_
17-31	2876-2879	the	_
17-32	2880-2889	Addiction	_
17-33	2890-2898	Severity	_
17-34	2899-2904	Index	_
17-35	2905-2906	(	_
17-36	2907-2912	ASI-C	_
17-37	2913-2914	)	_
17-38	2915-2916	.	_

Text=Clinicians assessed each participant ’ s addiction severity on seven areas: medical, employment/support status, alcohol, drug, legal, family/social, and psychiatric by using a 0–9 Likert scale.
18-1	2917-2927	Clinicians	_
18-2	2928-2936	assessed	_
18-3	2937-2941	each	_
18-4	2942-2953	participant	_
18-5	2954-2955	’	_
18-6	2956-2957	s	_
18-7	2958-2967	addiction	_
18-8	2968-2976	severity	_
18-9	2977-2979	on	_
18-10	2980-2985	seven	_
18-11	2986-2991	areas	_
18-12	2992-2993	:	_
18-13	2994-3001	medical	_
18-14	3002-3003	,	_
18-15	3004-3022	employment/support	_
18-16	3023-3029	status	_
18-17	3030-3031	,	_
18-18	3032-3039	alcohol	_
18-19	3040-3041	,	_
18-20	3042-3046	drug	_
18-21	3047-3048	,	_
18-22	3049-3054	legal	_
18-23	3055-3056	,	_
18-24	3057-3070	family/social	_
18-25	3071-3072	,	_
18-26	3073-3076	and	_
18-27	3077-3088	psychiatric	_
18-28	3089-3091	by	_
18-29	3092-3097	using	_
18-30	3098-3099	a	_
18-31	3100-3103	0–9	_
18-32	3104-3110	Likert	_
18-33	3111-3116	scale	_
18-34	3117-3118	.	_

Text=A higher score indicates a more serious problem.
19-1	3119-3120	A	_
19-2	3121-3127	higher	_
19-3	3128-3133	score	_
19-4	3134-3143	indicates	_
19-5	3144-3145	a	_
19-6	3146-3150	more	_
19-7	3151-3158	serious	_
19-8	3159-3166	problem	_
19-9	3167-3168	.	_

Text=The addiction severity of drugs was labeled as ASID.
20-1	3169-3172	The	_
20-2	3173-3182	addiction	_
20-3	3183-3191	severity	_
20-4	3192-3194	of	_
20-5	3195-3200	drugs	_
20-6	3201-3204	was	_
20-7	3205-3212	labeled	_
20-8	3213-3215	as	_
20-9	3216-3220	ASID	http://maven.renci.org/NeuroBridge/neurobridge#ResidualSchizophrenia
20-10	3221-3222	.	_

Text=Furthermore, the enrolled ATSA participants all had used amphetamine-type stimulants for more than one year, and the accumulated dosage of the amphetamine-type stimulants they used was above 50 g. Based on self-reports of these abusers, among the 17 ATSAs, 8 participants used methamphetamine only and 9 participants used two or three amphetamine-type stimulants, such as methamphetamine, ecstasy or ketamine.
21-1	3223-3234	Furthermore	_
21-2	3235-3236	,	_
21-3	3237-3240	the	_
21-4	3241-3249	enrolled	_
21-5	3250-3254	ATSA	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-6	3255-3267	participants	_
21-7	3268-3271	all	_
21-8	3272-3275	had	_
21-9	3276-3280	used	_
21-10	3281-3297	amphetamine-type	_
21-11	3298-3308	stimulants	_
21-12	3309-3312	for	_
21-13	3313-3317	more	_
21-14	3318-3322	than	_
21-15	3323-3326	one	_
21-16	3327-3331	year	_
21-17	3332-3333	,	_
21-18	3334-3337	and	_
21-19	3338-3341	the	_
21-20	3342-3353	accumulated	_
21-21	3354-3360	dosage	_
21-22	3361-3363	of	_
21-23	3364-3367	the	_
21-24	3368-3384	amphetamine-type	_
21-25	3385-3395	stimulants	_
21-26	3396-3400	they	_
21-27	3401-3405	used	_
21-28	3406-3409	was	_
21-29	3410-3415	above	_
21-30	3416-3418	50	_
21-31	3419-3421	g.	_
21-32	3422-3427	Based	_
21-33	3428-3430	on	_
21-34	3431-3443	self-reports	_
21-35	3444-3446	of	_
21-36	3447-3452	these	_
21-37	3453-3460	abusers	_
21-38	3461-3462	,	_
21-39	3463-3468	among	_
21-40	3469-3472	the	_
21-41	3473-3475	17	_
21-42	3476-3481	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
21-43	3482-3483	,	_
21-44	3484-3485	8	_
21-45	3486-3498	participants	_
21-46	3499-3503	used	_
21-47	3504-3519	methamphetamine	_
21-48	3520-3524	only	_
21-49	3525-3528	and	_
21-50	3529-3530	9	_
21-51	3531-3543	participants	_
21-52	3544-3548	used	_
21-53	3549-3552	two	_
21-54	3553-3555	or	_
21-55	3556-3561	three	_
21-56	3562-3578	amphetamine-type	_
21-57	3579-3589	stimulants	_
21-58	3590-3591	,	_
21-59	3592-3596	such	_
21-60	3597-3599	as	_
21-61	3600-3615	methamphetamine	_
21-62	3616-3617	,	_
21-63	3618-3625	ecstasy	_
21-64	3626-3628	or	_
21-65	3629-3637	ketamine	_
21-66	3638-3639	.	_

Text=None of the ATSAs and HCs had a history of abuse or dependence on other substances, with the exceptions of nicotine, caffeine, and alcohol.
22-1	3640-3644	None	_
22-2	3645-3647	of	_
22-3	3648-3651	the	_
22-4	3652-3657	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
22-5	3658-3661	and	_
22-6	3662-3665	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-7	3666-3669	had	_
22-8	3670-3671	a	_
22-9	3672-3679	history	_
22-10	3680-3682	of	_
22-11	3683-3688	abuse	_
22-12	3689-3691	or	_
22-13	3692-3702	dependence	_
22-14	3703-3705	on	_
22-15	3706-3711	other	_
22-16	3712-3722	substances	_
22-17	3723-3724	,	_
22-18	3725-3729	with	_
22-19	3730-3733	the	_
22-20	3734-3744	exceptions	_
22-21	3745-3747	of	_
22-22	3748-3756	nicotine	_
22-23	3757-3758	,	_
22-24	3759-3767	caffeine	_
22-25	3768-3769	,	_
22-26	3770-3773	and	_
22-27	3774-3781	alcohol	_
22-28	3782-3783	.	_

Text=All of the ATSAs were inpatients, so they were in a state of withdrawal from any substance.
23-1	3784-3787	All	_
23-2	3788-3790	of	_
23-3	3791-3794	the	_
23-4	3795-3800	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
23-5	3801-3805	were	_
23-6	3806-3816	inpatients	_
23-7	3817-3818	,	_
23-8	3819-3821	so	_
23-9	3822-3826	they	_
23-10	3827-3831	were	_
23-11	3832-3834	in	_
23-12	3835-3836	a	_
23-13	3837-3842	state	_
23-14	3843-3845	of	_
23-15	3846-3856	withdrawal	_
23-16	3857-3861	from	_
23-17	3862-3865	any	_
23-18	3866-3875	substance	_
23-19	3876-3877	.	_

Text=They didn ’ t take any medicine or other treatment during hospitalization.
24-1	3878-3882	They	_
24-2	3883-3887	didn	_
24-3	3888-3889	’	_
24-4	3890-3891	t	_
24-5	3892-3896	take	_
24-6	3897-3900	any	_
24-7	3901-3909	medicine	_
24-8	3910-3912	or	_
24-9	3913-3918	other	_
24-10	3919-3928	treatment	_
24-11	3929-3935	during	_
24-12	3936-3951	hospitalization	_
24-13	3952-3953	.	_

Text=One ATSA and one HC subject were later excluded from the study because of excessive head motion during the fMRI scan.
25-1	3954-3957	One	_
25-2	3958-3962	ATSA	http://maven.renci.org/NeuroBridge/neurobridge#Thing
25-3	3963-3966	and	_
25-4	3967-3970	one	_
25-5	3971-3973	HC	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
25-6	3974-3981	subject	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
25-7	3982-3986	were	_
25-8	3987-3992	later	_
25-9	3993-4001	excluded	_
25-10	4002-4006	from	_
25-11	4007-4010	the	_
25-12	4011-4016	study	_
25-13	4017-4024	because	_
25-14	4025-4027	of	_
25-15	4028-4037	excessive	_
25-16	4038-4042	head	_
25-17	4043-4049	motion	_
25-18	4050-4056	during	_
25-19	4057-4060	the	_
25-20	4061-4065	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
25-21	4066-4070	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
25-22	4071-4072	.	_

Text=This study was approved by the Ethics Committee of Wuhan Mental Health Centre.
26-1	4073-4077	This	_
26-2	4078-4083	study	_
26-3	4084-4087	was	_
26-4	4088-4096	approved	_
26-5	4097-4099	by	_
26-6	4100-4103	the	_
26-7	4104-4110	Ethics	_
26-8	4111-4120	Committee	_
26-9	4121-4123	of	_
26-10	4124-4129	Wuhan	_
26-11	4130-4136	Mental	_
26-12	4137-4143	Health	_
26-13	4144-4150	Centre	_
26-14	4151-4152	.	_

Text=All participants or families of ATSAs provided written informed consent before participation.
27-1	4153-4156	All	_
27-2	4157-4169	participants	_
27-3	4170-4172	or	_
27-4	4173-4181	families	_
27-5	4182-4184	of	_
27-6	4185-4190	ATSAs	http://maven.renci.org/NeuroBridge/neurobridge#UCSDPerformancebasedSkillsAssessment
27-7	4191-4199	provided	_
27-8	4200-4207	written	_
27-9	4208-4216	informed	_
27-10	4217-4224	consent	_
27-11	4225-4231	before	_
27-12	4232-4245	participation	_
27-13	4246-4247	.	_

Text=MRI data acquisition Images were acquired with a 1.5 Tesla MRI scanner (Model: GE Signa HDxt) in Zhongshan Hospital, Wuhan City, Hubei Province, China.
28-1	4248-4251	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-2	4252-4256	data	_
28-3	4257-4268	acquisition	_
28-4	4269-4275	Images	_
28-5	4276-4280	were	_
28-6	4281-4289	acquired	_
28-7	4290-4294	with	_
28-8	4295-4296	a	_
28-9	4297-4300	1.5	_
28-10	4301-4306	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-11	4307-4310	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-12	4311-4318	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-13	4319-4320	(	_
28-14	4321-4326	Model	_
28-15	4327-4328	:	_
28-16	4329-4331	GE	_
28-17	4332-4337	Signa	http://maven.renci.org/NeuroBridge/neurobridge#StudyDesign
28-18	4338-4342	HDxt	http://maven.renci.org/NeuroBridge/neurobridge#StudyDesign
28-19	4343-4344	)	_
28-20	4345-4347	in	_
28-21	4348-4357	Zhongshan	_
28-22	4358-4366	Hospital	_
28-23	4367-4368	,	_
28-24	4369-4374	Wuhan	_
28-25	4375-4379	City	_
28-26	4380-4381	,	_
28-27	4382-4387	Hubei	_
28-28	4388-4396	Province	_
28-29	4397-4398	,	_
28-30	4399-4404	China	_
28-31	4405-4406	.	_

Text=Whole-brain functional scans were collected using an echo-planar imaging (EPI) sequence (repetition time = 3000 ms; echo time = 40 ms; flip angle = 90°; matrix = 64 × 64; field of view = 220 × 220 mm2; number of slices = 33; slice thickness = 3 mm; slice gap = 1 mm).
29-1	4407-4418	Whole-brain	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeBrainDisorder
29-2	4419-4429	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-3	4430-4435	scans	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-4	4436-4440	were	_
29-5	4441-4450	collected	_
29-6	4451-4456	using	_
29-7	4457-4459	an	_
29-8	4460-4471	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
29-9	4472-4479	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
29-10	4480-4481	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
29-11	4482-4485	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
29-12	4486-4487	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
29-13	4488-4496	sequence	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
29-14	4497-4498	(	_
29-15	4499-4509	repetition	_
29-16	4510-4514	time	_
29-17	4515-4516	=	_
29-18	4517-4521	3000	_
29-19	4522-4524	ms	_
29-20	4525-4526	;	_
29-21	4527-4531	echo	_
29-22	4532-4536	time	_
29-23	4537-4538	=	_
29-24	4539-4541	40	_
29-25	4542-4544	ms	_
29-26	4545-4546	;	_
29-27	4547-4551	flip	_
29-28	4552-4557	angle	_
29-29	4558-4559	=	_
29-30	4560-4563	90°	_
29-31	4564-4565	;	_
29-32	4566-4572	matrix	_
29-33	4573-4574	=	_
29-34	4575-4577	64	_
29-35	4578-4579	×	_
29-36	4580-4582	64	_
29-37	4583-4584	;	_
29-38	4585-4590	field	_
29-39	4591-4593	of	_
29-40	4594-4598	view	_
29-41	4599-4600	=	_
29-42	4601-4604	220	_
29-43	4605-4606	×	_
29-44	4607-4610	220	_
29-45	4611-4614	mm2	_
29-46	4615-4616	;	_
29-47	4617-4623	number	_
29-48	4624-4626	of	_
29-49	4627-4633	slices	_
29-50	4634-4635	=	_
29-51	4636-4638	33	_
29-52	4639-4640	;	_
29-53	4641-4646	slice	_
29-54	4647-4656	thickness	_
29-55	4657-4658	=	_
29-56	4659-4660	3	_
29-57	4661-4663	mm	_
29-58	4664-4665	;	_
29-59	4666-4671	slice	_
29-60	4672-4675	gap	_
29-61	4676-4677	=	_
29-62	4678-4679	1	_
29-63	4680-4682	mm	_
29-64	4683-4684	)	_
29-65	4685-4686	.	_

Text=Each functional run contained 180 volumes.
30-1	4687-4691	Each	_
30-2	4692-4702	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
30-3	4703-4706	run	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
30-4	4707-4716	contained	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
30-5	4717-4720	180	_
30-6	4721-4728	volumes	_
30-7	4729-4730	.	_

Text=High-resolution T1-weighted images were acquired in a sagittal orientation employing a fast SPGR sequence (repetition/echo time = 9.176/2.956 ms; flip angle = 20°; slice thickness = 1.2 mm (no gap); number of slices = 128).
31-1	4731-4746	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
31-2	4747-4758	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
31-3	4759-4765	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
31-4	4766-4770	were	_
31-5	4771-4779	acquired	_
31-6	4780-4782	in	_
31-7	4783-4784	a	_
31-8	4785-4793	sagittal	_
31-9	4794-4805	orientation	_
31-10	4806-4815	employing	_
31-11	4816-4817	a	_
31-12	4818-4822	fast	_
31-13	4823-4827	SPGR	_
31-14	4828-4836	sequence	_
31-15	4837-4838	(	_
31-16	4839-4854	repetition/echo	_
31-17	4855-4859	time	_
31-18	4860-4861	=	_
31-19	4862-4873	9.176/2.956	_
31-20	4874-4876	ms	_
31-21	4877-4878	;	_
31-22	4879-4883	flip	_
31-23	4884-4889	angle	_
31-24	4890-4891	=	_
31-25	4892-4895	20°	_
31-26	4896-4897	;	_
31-27	4898-4903	slice	_
31-28	4904-4913	thickness	_
31-29	4914-4915	=	_
31-30	4916-4919	1.2	_
31-31	4920-4922	mm	_
31-32	4923-4924	(	_
31-33	4925-4927	no	_
31-34	4928-4931	gap	_
31-35	4932-4933	)	_
31-36	4934-4935	;	_
31-37	4936-4942	number	_
31-38	4943-4945	of	_
31-39	4946-4952	slices	_
31-40	4953-4954	=	_
31-41	4955-4958	128	_
31-42	4959-4960	)	_
31-43	4961-4962	.	_

Text=Data preprocessing Image preprocessing was performed using the Data Processing Assistant for Resting-State fMRI (DPARSF_v4.4, https: //rfmri.org/DPARSF), the Statistical Parametric Mapping (SPM12) program (https: //www.fil.ion.ucl.ac.uk/spm), and the Resting-State fMRI Data Analysis Toolkit (REST 1.8, https: //www.restfmri.net).
32-1	4963-4967	Data	_
32-2	4968-4981	preprocessing	_
32-3	4982-4987	Image	_
32-4	4988-5001	preprocessing	_
32-5	5002-5005	was	_
32-6	5006-5015	performed	_
32-7	5016-5021	using	_
32-8	5022-5025	the	_
32-9	5026-5030	Data	_
32-10	5031-5041	Processing	_
32-11	5042-5051	Assistant	_
32-12	5052-5055	for	_
32-13	5056-5069	Resting-State	_
32-14	5070-5074	fMRI	_
32-15	5075-5076	(	_
32-16	5077-5088	DPARSF_v4.4	_
32-17	5089-5090	,	_
32-18	5091-5096	https	_
32-19	5097-5098	:	_
32-20	5099-5117	//rfmri.org/DPARSF	_
32-21	5118-5119	)	_
32-22	5120-5121	,	_
32-23	5122-5125	the	_
32-24	5126-5137	Statistical	_
32-25	5138-5148	Parametric	_
32-26	5149-5156	Mapping	_
32-27	5157-5158	(	_
32-28	5159-5164	SPM12	_
32-29	5165-5166	)	_
32-30	5167-5174	program	_
32-31	5175-5176	(	_
32-32	5177-5182	https	_
32-33	5183-5184	:	_
32-34	5185-5212	//www.fil.ion.ucl.ac.uk/spm	_
32-35	5213-5214	)	_
32-36	5215-5216	,	_
32-37	5217-5220	and	_
32-38	5221-5224	the	_
32-39	5225-5238	Resting-State	_
32-40	5239-5243	fMRI	_
32-41	5244-5248	Data	_
32-42	5249-5257	Analysis	_
32-43	5258-5265	Toolkit	_
32-44	5266-5267	(	_
32-45	5268-5272	REST	_
32-46	5273-5276	1.8	_
32-47	5277-5278	,	_
32-48	5279-5284	https	_
32-49	5285-5286	:	_
32-50	5287-5305	//www.restfmri.net	_
32-51	5306-5307	)	_
32-52	5308-5309	.	_

Text=Before preprocessing, we discarded the first 10 volumes to allow for signal stabilization.
33-1	5310-5316	Before	_
33-2	5317-5330	preprocessing	_
33-3	5331-5332	,	_
33-4	5333-5335	we	_
33-5	5336-5345	discarded	_
33-6	5346-5349	the	_
33-7	5350-5355	first	_
33-8	5356-5358	10	_
33-9	5359-5366	volumes	_
33-10	5367-5369	to	_
33-11	5370-5375	allow	_
33-12	5376-5379	for	_
33-13	5380-5386	signal	_
33-14	5387-5400	stabilization	_
33-15	5401-5402	.	_

Text=The remaining volumes were corrected for differences in slice acquisition times and then realigned to correct for small movements that occurred between scans.
34-1	5403-5406	The	_
34-2	5407-5416	remaining	_
34-3	5417-5424	volumes	_
34-4	5425-5429	were	_
34-5	5430-5439	corrected	_
34-6	5440-5443	for	_
34-7	5444-5455	differences	_
34-8	5456-5458	in	_
34-9	5459-5464	slice	_
34-10	5465-5476	acquisition	_
34-11	5477-5482	times	_
34-12	5483-5486	and	_
34-13	5487-5491	then	_
34-14	5492-5501	realigned	_
34-15	5502-5504	to	_
34-16	5505-5512	correct	_
34-17	5513-5516	for	_
34-18	5517-5522	small	_
34-19	5523-5532	movements	_
34-20	5533-5537	that	_
34-21	5538-5546	occurred	_
34-22	5547-5554	between	_
34-23	5555-5560	scans	_
34-24	5561-5562	.	_

Text=Subjects with a maximum displacement of more than 3 mm (in the x, y, or z direction) or more than 3° of angular rotation about any axis for any of the 170 volumes were excluded from the study.
35-1	5563-5571	Subjects	_
35-2	5572-5576	with	_
35-3	5577-5578	a	_
35-4	5579-5586	maximum	_
35-5	5587-5599	displacement	_
35-6	5600-5602	of	_
35-7	5603-5607	more	_
35-8	5608-5612	than	_
35-9	5613-5614	3	_
35-10	5615-5617	mm	_
35-11	5618-5619	(	_
35-12	5620-5622	in	_
35-13	5623-5626	the	_
35-14	5627-5628	x	_
35-15	5629-5630	,	_
35-16	5631-5632	y	_
35-17	5633-5634	,	_
35-18	5635-5637	or	_
35-19	5638-5639	z	_
35-20	5640-5649	direction	_
35-21	5650-5651	)	_
35-22	5652-5654	or	_
35-23	5655-5659	more	_
35-24	5660-5664	than	_
35-25	5665-5667	3°	_
35-26	5668-5670	of	_
35-27	5671-5678	angular	_
35-28	5679-5687	rotation	_
35-29	5688-5693	about	_
35-30	5694-5697	any	_
35-31	5698-5702	axis	_
35-32	5703-5706	for	_
35-33	5707-5710	any	_
35-34	5711-5713	of	_
35-35	5714-5717	the	_
35-36	5718-5721	170	_
35-37	5722-5729	volumes	_
35-38	5730-5734	were	_
35-39	5735-5743	excluded	_
35-40	5744-5748	from	_
35-41	5749-5752	the	_
35-42	5753-5758	study	_
35-43	5759-5760	.	_

Text=One ATSA and one HC were excluded from the analyses based on the recorded motion correction estimates.
36-1	5761-5764	One	_
36-2	5765-5769	ATSA	http://maven.renci.org/NeuroBridge/neurobridge#Thing
36-3	5770-5773	and	_
36-4	5774-5777	one	_
36-5	5778-5780	HC	_
36-6	5781-5785	were	_
36-7	5786-5794	excluded	_
36-8	5795-5799	from	_
36-9	5800-5803	the	_
36-10	5804-5812	analyses	_
36-11	5813-5818	based	_
36-12	5819-5821	on	_
36-13	5822-5825	the	_
36-14	5826-5834	recorded	_
36-15	5835-5841	motion	_
36-16	5842-5852	correction	_
36-17	5853-5862	estimates	_
36-18	5863-5864	.	_

Text=The realigned EPI images were coregistered to individual T1-weighted structural images.
37-1	5865-5868	The	_
37-2	5869-5878	realigned	_
37-3	5879-5882	EPI	_
37-4	5883-5889	images	_
37-5	5890-5894	were	_
37-6	5895-5907	coregistered	_
37-7	5908-5910	to	_
37-8	5911-5921	individual	_
37-9	5922-5933	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-10	5934-5944	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-11	5945-5951	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-12	5952-5953	.	_

Text=The locations of the NAc subdivisions in normalized T1 images for each subject can be seen in Additional file 1: Figure S1 and S2.
38-1	5954-5957	The	_
38-2	5958-5967	locations	_
38-3	5968-5970	of	_
38-4	5971-5974	the	_
38-5	5975-5978	NAc	_
38-6	5979-5991	subdivisions	_
38-7	5992-5994	in	_
38-8	5995-6005	normalized	_
38-9	6006-6008	T1	_
38-10	6009-6015	images	_
38-11	6016-6019	for	_
38-12	6020-6024	each	_
38-13	6025-6032	subject	_
38-14	6033-6036	can	_
38-15	6037-6039	be	_
38-16	6040-6044	seen	_
38-17	6045-6047	in	_
38-18	6048-6058	Additional	_
38-19	6059-6063	file	_
38-20	6064-6065	1	_
38-21	6066-6067	:	_
38-22	6068-6074	Figure	_
38-23	6075-6077	S1	_
38-24	6078-6081	and	_
38-25	6082-6084	S2	_
38-26	6085-6086	.	_

Text=Then the transformed structural images were segmented into gray matter, white matter, and cerebrospinal fluid.
39-1	6087-6091	Then	_
39-2	6092-6095	the	_
39-3	6096-6107	transformed	_
39-4	6108-6118	structural	_
39-5	6119-6125	images	_
39-6	6126-6130	were	_
39-7	6131-6140	segmented	_
39-8	6141-6145	into	_
39-9	6146-6150	gray	_
39-10	6151-6157	matter	_
39-11	6158-6159	,	_
39-12	6160-6165	white	_
39-13	6166-6172	matter	_
39-14	6173-6174	,	_
39-15	6175-6178	and	_
39-16	6179-6192	cerebrospinal	_
39-17	6193-6198	fluid	_
39-18	6199-6200	.	_

Text=Several sources of variance were removed from the realigned data by regression of nuisance variables, including 24 motion parameters (6 head motion parameters, 6 head motion parameters one time point before, and the 12 corresponding squared items), the signal averaged over the individual segmented cerebrospinal fluid and white matter (WM) regions, linear and quadratic trends.
40-1	6201-6208	Several	_
40-2	6209-6216	sources	_
40-3	6217-6219	of	_
40-4	6220-6228	variance	_
40-5	6229-6233	were	_
40-6	6234-6241	removed	_
40-7	6242-6246	from	_
40-8	6247-6250	the	_
40-9	6251-6260	realigned	_
40-10	6261-6265	data	_
40-11	6266-6268	by	_
40-12	6269-6279	regression	_
40-13	6280-6282	of	_
40-14	6283-6291	nuisance	_
40-15	6292-6301	variables	_
40-16	6302-6303	,	_
40-17	6304-6313	including	_
40-18	6314-6316	24	_
40-19	6317-6323	motion	_
40-20	6324-6334	parameters	_
40-21	6335-6336	(	_
40-22	6337-6338	6	_
40-23	6339-6343	head	_
40-24	6344-6350	motion	_
40-25	6351-6361	parameters	_
40-26	6362-6363	,	_
40-27	6364-6365	6	_
40-28	6366-6370	head	_
40-29	6371-6377	motion	_
40-30	6378-6388	parameters	_
40-31	6389-6392	one	_
40-32	6393-6397	time	_
40-33	6398-6403	point	_
40-34	6404-6410	before	_
40-35	6411-6412	,	_
40-36	6413-6416	and	_
40-37	6417-6420	the	_
40-38	6421-6423	12	_
40-39	6424-6437	corresponding	_
40-40	6438-6445	squared	_
40-41	6446-6451	items	_
40-42	6452-6453	)	_
40-43	6454-6455	,	_
40-44	6456-6459	the	_
40-45	6460-6466	signal	_
40-46	6467-6475	averaged	_
40-47	6476-6480	over	_
40-48	6481-6484	the	_
40-49	6485-6495	individual	_
40-50	6496-6505	segmented	_
40-51	6506-6519	cerebrospinal	_
40-52	6520-6525	fluid	_
40-53	6526-6529	and	_
40-54	6530-6535	white	_
40-55	6536-6542	matter	_
40-56	6543-6544	(	_
40-57	6545-6547	WM	_
40-58	6548-6549	)	_
40-59	6550-6557	regions	_
40-60	6558-6559	,	_
40-61	6560-6566	linear	_
40-62	6567-6570	and	_
40-63	6571-6580	quadratic	_
40-64	6581-6587	trends	_
40-65	6588-6589	.	_

Text=The resulting maps were then registered into MNI space with 2 × 2 × 2 mm3 cubic voxels using the transformation information acquired from T1 image unified segmentation.
41-1	6590-6593	The	_
41-2	6594-6603	resulting	_
41-3	6604-6608	maps	_
41-4	6609-6613	were	_
41-5	6614-6618	then	_
41-6	6619-6629	registered	_
41-7	6630-6634	into	_
41-8	6635-6638	MNI	_
41-9	6639-6644	space	_
41-10	6645-6649	with	_
41-11	6650-6651	2	_
41-12	6652-6653	×	_
41-13	6654-6655	2	_
41-14	6656-6657	×	_
41-15	6658-6659	2	_
41-16	6660-6663	mm3	_
41-17	6664-6669	cubic	_
41-18	6670-6676	voxels	_
41-19	6677-6682	using	_
41-20	6683-6686	the	_
41-21	6687-6701	transformation	_
41-22	6702-6713	information	_
41-23	6714-6722	acquired	_
41-24	6723-6727	from	_
41-25	6728-6730	T1	_
41-26	6731-6736	image	_
41-27	6737-6744	unified	_
41-28	6745-6757	segmentation	_
41-29	6758-6759	.	_

Text=A smoothing kernel of 4 mm was applied after registration.
42-1	6760-6761	A	_
42-2	6762-6771	smoothing	_
42-3	6772-6778	kernel	_
42-4	6779-6781	of	_
42-5	6782-6783	4	_
42-6	6784-6786	mm	_
42-7	6787-6790	was	_
42-8	6791-6798	applied	_
42-9	6799-6804	after	_
42-10	6805-6817	registration	_
42-11	6818-6819	.	_

Text=Finally, temporal filtering (0.01–0.1 Hz) of the time series was performed.
43-1	6820-6827	Finally	_
43-2	6828-6829	,	_
43-3	6830-6838	temporal	_
43-4	6839-6848	filtering	_
43-5	6849-6850	(	_
43-6	6851-6859	0.01–0.1	_
43-7	6860-6862	Hz	_
43-8	6863-6864	)	_
43-9	6865-6867	of	_
43-10	6868-6871	the	_
43-11	6872-6876	time	_
43-12	6877-6883	series	_
43-13	6884-6887	was	_
43-14	6888-6897	performed	_
43-15	6898-6899	.	_

Text=To characterize differences in in-scanner microhead motion, the mean frame-wise displacement (FD), which includes measures of voxel-wise differences in motion in its derivation, was used as a measure of the micro-head motion of each subject.
44-1	6900-6902	To	_
44-2	6903-6915	characterize	_
44-3	6916-6927	differences	_
44-4	6928-6930	in	_
44-5	6931-6941	in-scanner	_
44-6	6942-6951	microhead	_
44-7	6952-6958	motion	_
44-8	6959-6960	,	_
44-9	6961-6964	the	_
44-10	6965-6969	mean	_
44-11	6970-6980	frame-wise	_
44-12	6981-6993	displacement	_
44-13	6994-6995	(	_
44-14	6996-6998	FD	_
44-15	6999-7000	)	_
44-16	7001-7002	,	_
44-17	7003-7008	which	_
44-18	7009-7017	includes	_
44-19	7018-7026	measures	_
44-20	7027-7029	of	_
44-21	7030-7040	voxel-wise	_
44-22	7041-7052	differences	_
44-23	7053-7055	in	_
44-24	7056-7062	motion	_
44-25	7063-7065	in	_
44-26	7066-7069	its	_
44-27	7070-7080	derivation	_
44-28	7081-7082	,	_
44-29	7083-7086	was	_
44-30	7087-7091	used	_
44-31	7092-7094	as	_
44-32	7095-7096	a	_
44-33	7097-7104	measure	_
44-34	7105-7107	of	_
44-35	7108-7111	the	_
44-36	7112-7122	micro-head	_
44-37	7123-7129	motion	_
44-38	7130-7132	of	_
44-39	7133-7137	each	_
44-40	7138-7145	subject	_
44-41	7146-7147	.	_

Text=Definition of the regions of interest Using neuroanatomy and histochemistry, the differentiation of the NAc subregions has been extensively studied, yielding a widely-accepted dichotomic shell/core-like subdivisions that reflect dissociable roles respectively.
45-1	7148-7158	Definition	_
45-2	7159-7161	of	_
45-3	7162-7165	the	_
45-4	7166-7173	regions	_
45-5	7174-7176	of	_
45-6	7177-7185	interest	_
45-7	7186-7191	Using	_
45-8	7192-7204	neuroanatomy	_
45-9	7205-7208	and	_
45-10	7209-7223	histochemistry	_
45-11	7224-7225	,	_
45-12	7226-7229	the	_
45-13	7230-7245	differentiation	_
45-14	7246-7248	of	_
45-15	7249-7252	the	_
45-16	7253-7256	NAc	_
45-17	7257-7267	subregions	_
45-18	7268-7271	has	_
45-19	7272-7276	been	_
45-20	7277-7288	extensively	_
45-21	7289-7296	studied	_
45-22	7297-7298	,	_
45-23	7299-7307	yielding	_
45-24	7308-7309	a	_
45-25	7310-7325	widely-accepted	_
45-26	7326-7336	dichotomic	_
45-27	7337-7352	shell/core-like	_
45-28	7353-7365	subdivisions	_
45-29	7366-7370	that	_
45-30	7371-7378	reflect	_
45-31	7379-7390	dissociable	_
45-32	7391-7396	roles	_
45-33	7397-7409	respectively	_
45-34	7410-7411	.	_

Text=Recently, to investigate the regional differentiation within the NAc, Xia et al.
46-1	7412-7420	Recently	_
46-2	7421-7422	,	_
46-3	7423-7425	to	_
46-4	7426-7437	investigate	_
46-5	7438-7441	the	_
46-6	7442-7450	regional	_
46-7	7451-7466	differentiation	_
46-8	7467-7473	within	_
46-9	7474-7477	the	_
46-10	7478-7481	NAc	_
46-11	7482-7483	,	_
46-12	7484-7487	Xia	_
46-13	7488-7490	et	_
46-14	7491-7493	al	_
46-15	7494-7495	.	_

Text=used three complementary parcellation schemes based on tractography, RSFC, and task-dependent co-activation and found that the 2-cluster solution with shell/core architecture provided the best description of the data.
47-1	7496-7500	used	_
47-2	7501-7506	three	_
47-3	7507-7520	complementary	_
47-4	7521-7533	parcellation	_
47-5	7534-7541	schemes	_
47-6	7542-7547	based	_
47-7	7548-7550	on	_
47-8	7551-7563	tractography	_
47-9	7564-7565	,	_
47-10	7566-7570	RSFC	_
47-11	7571-7572	,	_
47-12	7573-7576	and	_
47-13	7577-7591	task-dependent	_
47-14	7592-7605	co-activation	_
47-15	7606-7609	and	_
47-16	7610-7615	found	_
47-17	7616-7620	that	_
47-18	7621-7624	the	_
47-19	7625-7634	2-cluster	_
47-20	7635-7643	solution	_
47-21	7644-7648	with	_
47-22	7649-7659	shell/core	_
47-23	7660-7672	architecture	_
47-24	7673-7681	provided	_
47-25	7682-7685	the	_
47-26	7686-7690	best	_
47-27	7691-7702	description	_
47-28	7703-7705	of	_
47-29	7706-7709	the	_
47-30	7710-7714	data	_
47-31	7715-7716	.	_

Text=The clusters generated in this solution across the three parcellation schemes were defined as the final parcels.
48-1	7717-7720	The	_
48-2	7721-7729	clusters	_
48-3	7730-7739	generated	_
48-4	7740-7742	in	_
48-5	7743-7747	this	_
48-6	7748-7756	solution	_
48-7	7757-7763	across	_
48-8	7764-7767	the	_
48-9	7768-7773	three	_
48-10	7774-7786	parcellation	_
48-11	7787-7794	schemes	_
48-12	7795-7799	were	_
48-13	7800-7807	defined	_
48-14	7808-7810	as	_
48-15	7811-7814	the	_
48-16	7815-7820	final	_
48-17	7821-7828	parcels	_
48-18	7829-7830	.	_

Text=In our study, the subdivisions of the NAc derived from RSFC patterns of these parcels were chosen as the regions of interests for further functional connectivity analyses (Fig.
49-1	7831-7833	In	_
49-2	7834-7837	our	_
49-3	7838-7843	study	_
49-4	7844-7845	,	_
49-5	7846-7849	the	_
49-6	7850-7862	subdivisions	_
49-7	7863-7865	of	_
49-8	7866-7869	the	_
49-9	7870-7873	NAc	_
49-10	7874-7881	derived	_
49-11	7882-7886	from	_
49-12	7887-7891	RSFC	_
49-13	7892-7900	patterns	_
49-14	7901-7903	of	_
49-15	7904-7909	these	_
49-16	7910-7917	parcels	_
49-17	7918-7922	were	_
49-18	7923-7929	chosen	_
49-19	7930-7932	as	_
49-20	7933-7936	the	_
49-21	7937-7944	regions	_
49-22	7945-7947	of	_
49-23	7948-7957	interests	_
49-24	7958-7961	for	_
49-25	7962-7969	further	_
49-26	7970-7980	functional	_
49-27	7981-7993	connectivity	_
49-28	7994-8002	analyses	_
49-29	8003-8004	(	_
49-30	8005-8008	Fig	_
49-31	8009-8010	.	_

Text=1).
50-1	8011-8012	1	_
50-2	8013-8014	)	_
50-3	8015-8016	.	_

Text=RSFC analyses The seed-based RSFC of the four subdivisions of the NAc was analyzed.
51-1	8017-8021	RSFC	_
51-2	8022-8030	analyses	_
51-3	8031-8034	The	_
51-4	8035-8045	seed-based	_
51-5	8046-8050	RSFC	_
51-6	8051-8053	of	_
51-7	8054-8057	the	_
51-8	8058-8062	four	_
51-9	8063-8075	subdivisions	_
51-10	8076-8078	of	_
51-11	8079-8082	the	_
51-12	8083-8086	NAc	_
51-13	8087-8090	was	_
51-14	8091-8099	analyzed	_
51-15	8100-8101	.	_

Text=By averaging the time series of all of the voxels within the seed region, the mean time series of each seed region was acquired.
52-1	8102-8104	By	_
52-2	8105-8114	averaging	_
52-3	8115-8118	the	_
52-4	8119-8123	time	_
52-5	8124-8130	series	_
52-6	8131-8133	of	_
52-7	8134-8137	all	_
52-8	8138-8140	of	_
52-9	8141-8144	the	_
52-10	8145-8151	voxels	_
52-11	8152-8158	within	_
52-12	8159-8162	the	_
52-13	8163-8167	seed	_
52-14	8168-8174	region	_
52-15	8175-8176	,	_
52-16	8177-8180	the	_
52-17	8181-8185	mean	_
52-18	8186-8190	time	_
52-19	8191-8197	series	_
52-20	8198-8200	of	_
52-21	8201-8205	each	_
52-22	8206-8210	seed	_
52-23	8211-8217	region	_
52-24	8218-8221	was	_
52-25	8222-8230	acquired	_
52-26	8231-8232	.	_

Text=Pearson ’ s correlation coefficients were computed between the mean time series of the seed region and time series of each voxel of the whole brain.
53-1	8233-8240	Pearson	_
53-2	8241-8242	’	_
53-3	8243-8244	s	_
53-4	8245-8256	correlation	_
53-5	8257-8269	coefficients	_
53-6	8270-8274	were	_
53-7	8275-8283	computed	_
53-8	8284-8291	between	_
53-9	8292-8295	the	_
53-10	8296-8300	mean	_
53-11	8301-8305	time	_
53-12	8306-8312	series	_
53-13	8313-8315	of	_
53-14	8316-8319	the	_
53-15	8320-8324	seed	_
53-16	8325-8331	region	_
53-17	8332-8335	and	_
53-18	8336-8340	time	_
53-19	8341-8347	series	_
53-20	8348-8350	of	_
53-21	8351-8355	each	_
53-22	8356-8361	voxel	_
53-23	8362-8364	of	_
53-24	8365-8368	the	_
53-25	8369-8374	whole	_
53-26	8375-8380	brain	_
53-27	8381-8382	.	_

Text=The correlation coefficients were converted into z-values using Fisher ’ s r-to-z transformation in order to improve their normality.
54-1	8383-8386	The	_
54-2	8387-8398	correlation	_
54-3	8399-8411	coefficients	_
54-4	8412-8416	were	_
54-5	8417-8426	converted	_
54-6	8427-8431	into	_
54-7	8432-8440	z-values	_
54-8	8441-8446	using	_
54-9	8447-8453	Fisher	_
54-10	8454-8455	’	_
54-11	8456-8457	s	_
54-12	8458-8464	r-to-z	_
54-13	8465-8479	transformation	_
54-14	8480-8482	in	_
54-15	8483-8488	order	_
54-16	8489-8491	to	_
54-17	8492-8499	improve	_
54-18	8500-8505	their	_
54-19	8506-8515	normality	_
54-20	8516-8517	.	_

Text=The z-values were analyzed by one-sample t-tests to identify brain regions that exhibited significant positive or negative correlations with the seed region within each group (voxel-wise p <0.001, cluster-wise FWE p <0.05).
55-1	8518-8521	The	_
55-2	8522-8530	z-values	_
55-3	8531-8535	were	_
55-4	8536-8544	analyzed	_
55-5	8545-8547	by	_
55-6	8548-8558	one-sample	_
55-7	8559-8566	t-tests	_
55-8	8567-8569	to	_
55-9	8570-8578	identify	_
55-10	8579-8584	brain	_
55-11	8585-8592	regions	_
55-12	8593-8597	that	_
55-13	8598-8607	exhibited	_
55-14	8608-8619	significant	_
55-15	8620-8628	positive	_
55-16	8629-8631	or	_
55-17	8632-8640	negative	_
55-18	8641-8653	correlations	_
55-19	8654-8658	with	_
55-20	8659-8662	the	_
55-21	8663-8667	seed	_
55-22	8668-8674	region	_
55-23	8675-8681	within	_
55-24	8682-8686	each	_
55-25	8687-8692	group	_
55-26	8693-8694	(	_
55-27	8695-8705	voxel-wise	_
55-28	8706-8707	p	_
55-29	8708-8709	<	_
55-30	8710-8715	0.001	_
55-31	8716-8717	,	_
55-32	8718-8730	cluster-wise	_
55-33	8731-8734	FWE	_
55-34	8735-8736	p	_
55-35	8737-8738	<	_
55-36	8739-8743	0.05	_
55-37	8744-8745	)	_
55-38	8746-8747	.	_

Text=Finally, the z-values were analyzed by two-sample t-tests to identify brain regions that exhibited significant differences in connectivity with the seed region between the ATSA group and HC group while accounting for the confounding effects of the education level, age and Jenkinson ’ s mean FD.
56-1	8748-8755	Finally	_
56-2	8756-8757	,	_
56-3	8758-8761	the	_
56-4	8762-8770	z-values	_
56-5	8771-8775	were	_
56-6	8776-8784	analyzed	_
56-7	8785-8787	by	_
56-8	8788-8798	two-sample	_
56-9	8799-8806	t-tests	_
56-10	8807-8809	to	_
56-11	8810-8818	identify	_
56-12	8819-8824	brain	_
56-13	8825-8832	regions	_
56-14	8833-8837	that	_
56-15	8838-8847	exhibited	_
56-16	8848-8859	significant	_
56-17	8860-8871	differences	_
56-18	8872-8874	in	_
56-19	8875-8887	connectivity	_
56-20	8888-8892	with	_
56-21	8893-8896	the	_
56-22	8897-8901	seed	_
56-23	8902-8908	region	_
56-24	8909-8916	between	_
56-25	8917-8920	the	_
56-26	8921-8925	ATSA	_
56-27	8926-8931	group	_
56-28	8932-8935	and	_
56-29	8936-8938	HC	_
56-30	8939-8944	group	_
56-31	8945-8950	while	_
56-32	8951-8961	accounting	_
56-33	8962-8965	for	_
56-34	8966-8969	the	_
56-35	8970-8981	confounding	_
56-36	8982-8989	effects	_
56-37	8990-8992	of	_
56-38	8993-8996	the	_
56-39	8997-9006	education	_
56-40	9007-9012	level	_
56-41	9013-9014	,	_
56-42	9015-9018	age	_
56-43	9019-9022	and	_
56-44	9023-9032	Jenkinson	_
56-45	9033-9034	’	_
56-46	9035-9036	s	_
56-47	9037-9041	mean	_
56-48	9042-9044	FD	_
56-49	9045-9046	.	_

Text=The statistical threshold of the two-sample t-test was set at voxel-wise p <0.001 in conjunction with a cluster-wise FWE p <0.0125 to correct for multiple comparisons [p <0.0125 was selected to take in account the number of independent seed regions used (0.0125 = 0.05/4)].
57-1	9047-9050	The	_
57-2	9051-9062	statistical	_
57-3	9063-9072	threshold	_
57-4	9073-9075	of	_
57-5	9076-9079	the	_
57-6	9080-9090	two-sample	_
57-7	9091-9097	t-test	_
57-8	9098-9101	was	_
57-9	9102-9105	set	_
57-10	9106-9108	at	_
57-11	9109-9119	voxel-wise	_
57-12	9120-9121	p	_
57-13	9122-9123	<	_
57-14	9124-9129	0.001	_
57-15	9130-9132	in	_
57-16	9133-9144	conjunction	_
57-17	9145-9149	with	_
57-18	9150-9151	a	_
57-19	9152-9164	cluster-wise	_
57-20	9165-9168	FWE	_
57-21	9169-9170	p	_
57-22	9171-9172	<	_
57-23	9173-9179	0.0125	_
57-24	9180-9182	to	_
57-25	9183-9190	correct	_
57-26	9191-9194	for	_
57-27	9195-9203	multiple	_
57-28	9204-9215	comparisons	_
57-29	9216-9217	[	_
57-30	9218-9219	p	_
57-31	9220-9221	<	_
57-32	9222-9228	0.0125	_
57-33	9229-9232	was	_
57-34	9233-9241	selected	_
57-35	9242-9244	to	_
57-36	9245-9249	take	_
57-37	9250-9252	in	_
57-38	9253-9260	account	_
57-39	9261-9264	the	_
57-40	9265-9271	number	_
57-41	9272-9274	of	_
57-42	9275-9286	independent	_
57-43	9287-9291	seed	_
57-44	9292-9299	regions	_
57-45	9300-9304	used	_
57-46	9305-9306	(	_
57-47	9307-9313	0.0125	_
57-48	9314-9315	=	_
57-49	9316-9322	0.05/4	_
57-50	9323-9324	)	_
57-51	9325-9326	]	_
57-52	9327-9328	.	_

Text=Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
58-1	9329-9341	Availability	_
58-2	9342-9344	of	_
58-3	9345-9349	data	_
58-4	9350-9353	and	_
58-5	9354-9363	materials	_
58-6	9364-9367	The	_
58-7	9368-9376	datasets	_
58-8	9377-9381	used	_
58-9	9382-9388	and/or	_
58-10	9389-9397	analyzed	_
58-11	9398-9404	during	_
58-12	9405-9408	the	_
58-13	9409-9416	current	_
58-14	9417-9422	study	_
58-15	9423-9426	are	_
58-16	9427-9436	available	_
58-17	9437-9441	from	_
58-18	9442-9445	the	_
58-19	9446-9459	corresponding	_
58-20	9460-9466	author	_
58-21	9467-9469	on	_
58-22	9470-9480	reasonable	_
58-23	9481-9488	request	_
58-24	9489-9490	.	_

Text=Ethics approval and consent to participate This study was approved by the Ethics Committee of Wuhan Mental Health Centre.
59-1	9491-9497	Ethics	_
59-2	9498-9506	approval	_
59-3	9507-9510	and	_
59-4	9511-9518	consent	_
59-5	9519-9521	to	_
59-6	9522-9533	participate	_
59-7	9534-9538	This	_
59-8	9539-9544	study	_
59-9	9545-9548	was	_
59-10	9549-9557	approved	_
59-11	9558-9560	by	_
59-12	9561-9564	the	_
59-13	9565-9571	Ethics	_
59-14	9572-9581	Committee	_
59-15	9582-9584	of	_
59-16	9585-9590	Wuhan	_
59-17	9591-9597	Mental	_
59-18	9598-9604	Health	_
59-19	9605-9611	Centre	_
59-20	9612-9613	.	_

Text=All participants or families of ATSAs provided informed consent before participation.
60-1	9614-9617	All	_
60-2	9618-9630	participants	_
60-3	9631-9633	or	_
60-4	9634-9642	families	_
60-5	9643-9645	of	_
60-6	9646-9651	ATSAs	_
60-7	9652-9660	provided	_
60-8	9661-9669	informed	_
60-9	9670-9677	consent	_
60-10	9678-9684	before	_
60-11	9685-9698	participation	_
60-12	9699-9700	.	_

Text=Consent for publication Not applicable.
61-1	9701-9708	Consent	_
61-2	9709-9712	for	_
61-3	9713-9724	publication	_
61-4	9725-9728	Not	_
61-5	9729-9739	applicable	_
61-6	9740-9741	.	_

